What is HC Wainwright’s Forecast for LEXX FY2025 Earnings?

Lexaria Bioscience Corp. (NASDAQ:LEXX) – HC Wainwright decreased their FY2025 EPS estimates for shares of Lexaria Bioscience in a report issued on Tuesday, July 1st. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.62) per share for the year, down from their previous forecast of ($0.60). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Lexaria Bioscience’s Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.49) EPS.

Lexaria Bioscience (NASDAQ:LEXX) last posted its earnings results on Monday, April 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Lexaria Bioscience had a negative net margin of 1,784.03% and a negative return on equity of 111.84%. The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.14 million.

Lexaria Bioscience Stock Performance

NASDAQ LEXX opened at $0.90 on Thursday. The firm has a market capitalization of $15.72 million, a P/E ratio of -1.52 and a beta of 0.79. The stock has a 50-day simple moving average of $1.02 and a two-hundred day simple moving average of $1.47. Lexaria Bioscience has a fifty-two week low of $0.82 and a fifty-two week high of $4.38.

Institutional Trading of Lexaria Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of LEXX. HighTower Advisors LLC lifted its holdings in Lexaria Bioscience by 61.4% in the fourth quarter. HighTower Advisors LLC now owns 21,023 shares of the company’s stock valued at $44,000 after acquiring an additional 8,000 shares during the period. Byrne Asset Management LLC grew its stake in shares of Lexaria Bioscience by 122.3% during the 1st quarter. Byrne Asset Management LLC now owns 28,905 shares of the company’s stock worth $49,000 after purchasing an additional 15,905 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in shares of Lexaria Bioscience by 108.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,873 shares of the company’s stock worth $61,000 after purchasing an additional 15,050 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Lexaria Bioscience during the 4th quarter valued at approximately $127,000. Finally, Geode Capital Management LLC lifted its stake in shares of Lexaria Bioscience by 10.8% in the 4th quarter. Geode Capital Management LLC now owns 166,679 shares of the company’s stock valued at $350,000 after purchasing an additional 16,288 shares during the period. 13.06% of the stock is owned by institutional investors and hedge funds.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.